SEC Form 4 · accession 0001179110-17-012396
Allergan plc · AGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brent L Saunders
Officer — Chairman, President and CEO · Director
Period of report
Mar 29, 2017
Accepted (ET)
Sep 18, 2017 · 8:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001578845
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, par value $0.001F1,F3 | Mar 29, 2017 | P | 43 | $242.21 | A | 131,135 | D | |
| Ordinary Shares, par value $0.001F2,F3 | Jun 16, 2017 | P | 44 | $235.96 | A | 131,178 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 42.52 shares acquired on March 29, 2017 pursuant to a broker-assisted dividend reinvestment plan.
- F2Includes 43.7680 shares acquired on June 16, 2017 pursuant to a broker-assisted dividend reinvestment plan.
- F3Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.